Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)

Stefan Kölker, E. Christensen, J. V. Leonard, C. R. Greenberg, A. B. Burlina, A. P. Burlina, M. Dixon, M. Duran, S. I. Goodman, David Koeller, E. Müller, E. R. Naughten, E. Neumaier-Probst, J. G. Okun, M. Kyllerman, R. A. Surtees, B. Wilcken, G. F. Hoffmann, P. Burgard

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Glutaryl-CoA dehydrogenase (GCDH) deficiency is an autosomal recessive disease with an estimated overall prevalence of 1 in 100 000 newborns. Biochemically, the disease is characterized by accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine, which can be detected by gas chromatography-mass spectrometry of organic acids or tandem mass spectrometry of acylcarnitines. Clinically, the disease course is usually determined by acute encephalopathic crises precipitated by infectious diseases, immunizations, and surgery during infancy or childhood. The characteristic neurological sequel is acute striatal injury and, subsequently, dystonia. During the last three decades attempts have been made to establish and optimize therapy for GCDH deficiency. Maintenance treatment consisting of a diet combined with oral supplementation of L-carnitine, and an intensified emergency treatment during acute episodes of intercurrent illness have been applied to the majority of patients. This treatment strategy has significantly reduced the frequency of acute encephalopathic crises in early-diagnosed patients. Therefore, GCDH deficiency is now considered to be a treatable condition. However, significant differences exist in the diagnostic procedure and management of affected patients so that there is a wide variation of the outcome, in particular of pre-symptomatically diagnosed patients. At this time of rapid expansion of neonatal screening for GCDH deficiency, the major aim of this guideline is to re-assess the common practice and to formulate recommendations for diagnosis and management of GCDH deficiency based on the best available evidence.

Original languageEnglish (US)
Pages (from-to)5-22
Number of pages18
JournalJournal of Inherited Metabolic Disease
Volume30
Issue number1
DOIs
StatePublished - Feb 2007

Fingerprint

Guidelines
Corpus Striatum
Neonatal Screening
Emergency Treatment
Dystonia
Carnitine
Tandem Mass Spectrometry
Gas Chromatography-Mass Spectrometry
Communicable Diseases
Immunization
Therapeutics
Glutaric Acidemia I
Newborn Infant
Diet
Acids
Wounds and Injuries

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Endocrinology

Cite this

Kölker, S., Christensen, E., Leonard, J. V., Greenberg, C. R., Burlina, A. B., Burlina, A. P., ... Burgard, P. (2007). Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). Journal of Inherited Metabolic Disease, 30(1), 5-22. https://doi.org/10.1007/s10545-006-0451-4

Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). / Kölker, Stefan; Christensen, E.; Leonard, J. V.; Greenberg, C. R.; Burlina, A. B.; Burlina, A. P.; Dixon, M.; Duran, M.; Goodman, S. I.; Koeller, David; Müller, E.; Naughten, E. R.; Neumaier-Probst, E.; Okun, J. G.; Kyllerman, M.; Surtees, R. A.; Wilcken, B.; Hoffmann, G. F.; Burgard, P.

In: Journal of Inherited Metabolic Disease, Vol. 30, No. 1, 02.2007, p. 5-22.

Research output: Contribution to journalArticle

Kölker, S, Christensen, E, Leonard, JV, Greenberg, CR, Burlina, AB, Burlina, AP, Dixon, M, Duran, M, Goodman, SI, Koeller, D, Müller, E, Naughten, ER, Neumaier-Probst, E, Okun, JG, Kyllerman, M, Surtees, RA, Wilcken, B, Hoffmann, GF & Burgard, P 2007, 'Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)', Journal of Inherited Metabolic Disease, vol. 30, no. 1, pp. 5-22. https://doi.org/10.1007/s10545-006-0451-4
Kölker, Stefan ; Christensen, E. ; Leonard, J. V. ; Greenberg, C. R. ; Burlina, A. B. ; Burlina, A. P. ; Dixon, M. ; Duran, M. ; Goodman, S. I. ; Koeller, David ; Müller, E. ; Naughten, E. R. ; Neumaier-Probst, E. ; Okun, J. G. ; Kyllerman, M. ; Surtees, R. A. ; Wilcken, B. ; Hoffmann, G. F. ; Burgard, P. / Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). In: Journal of Inherited Metabolic Disease. 2007 ; Vol. 30, No. 1. pp. 5-22.
@article{1f5df1508f0f4266909cf8a893cfdc4e,
title = "Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)",
abstract = "Glutaryl-CoA dehydrogenase (GCDH) deficiency is an autosomal recessive disease with an estimated overall prevalence of 1 in 100 000 newborns. Biochemically, the disease is characterized by accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine, which can be detected by gas chromatography-mass spectrometry of organic acids or tandem mass spectrometry of acylcarnitines. Clinically, the disease course is usually determined by acute encephalopathic crises precipitated by infectious diseases, immunizations, and surgery during infancy or childhood. The characteristic neurological sequel is acute striatal injury and, subsequently, dystonia. During the last three decades attempts have been made to establish and optimize therapy for GCDH deficiency. Maintenance treatment consisting of a diet combined with oral supplementation of L-carnitine, and an intensified emergency treatment during acute episodes of intercurrent illness have been applied to the majority of patients. This treatment strategy has significantly reduced the frequency of acute encephalopathic crises in early-diagnosed patients. Therefore, GCDH deficiency is now considered to be a treatable condition. However, significant differences exist in the diagnostic procedure and management of affected patients so that there is a wide variation of the outcome, in particular of pre-symptomatically diagnosed patients. At this time of rapid expansion of neonatal screening for GCDH deficiency, the major aim of this guideline is to re-assess the common practice and to formulate recommendations for diagnosis and management of GCDH deficiency based on the best available evidence.",
author = "Stefan K{\"o}lker and E. Christensen and Leonard, {J. V.} and Greenberg, {C. R.} and Burlina, {A. B.} and Burlina, {A. P.} and M. Dixon and M. Duran and Goodman, {S. I.} and David Koeller and E. M{\"u}ller and Naughten, {E. R.} and E. Neumaier-Probst and Okun, {J. G.} and M. Kyllerman and Surtees, {R. A.} and B. Wilcken and Hoffmann, {G. F.} and P. Burgard",
year = "2007",
month = "2",
doi = "10.1007/s10545-006-0451-4",
language = "English (US)",
volume = "30",
pages = "5--22",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)

AU - Kölker, Stefan

AU - Christensen, E.

AU - Leonard, J. V.

AU - Greenberg, C. R.

AU - Burlina, A. B.

AU - Burlina, A. P.

AU - Dixon, M.

AU - Duran, M.

AU - Goodman, S. I.

AU - Koeller, David

AU - Müller, E.

AU - Naughten, E. R.

AU - Neumaier-Probst, E.

AU - Okun, J. G.

AU - Kyllerman, M.

AU - Surtees, R. A.

AU - Wilcken, B.

AU - Hoffmann, G. F.

AU - Burgard, P.

PY - 2007/2

Y1 - 2007/2

N2 - Glutaryl-CoA dehydrogenase (GCDH) deficiency is an autosomal recessive disease with an estimated overall prevalence of 1 in 100 000 newborns. Biochemically, the disease is characterized by accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine, which can be detected by gas chromatography-mass spectrometry of organic acids or tandem mass spectrometry of acylcarnitines. Clinically, the disease course is usually determined by acute encephalopathic crises precipitated by infectious diseases, immunizations, and surgery during infancy or childhood. The characteristic neurological sequel is acute striatal injury and, subsequently, dystonia. During the last three decades attempts have been made to establish and optimize therapy for GCDH deficiency. Maintenance treatment consisting of a diet combined with oral supplementation of L-carnitine, and an intensified emergency treatment during acute episodes of intercurrent illness have been applied to the majority of patients. This treatment strategy has significantly reduced the frequency of acute encephalopathic crises in early-diagnosed patients. Therefore, GCDH deficiency is now considered to be a treatable condition. However, significant differences exist in the diagnostic procedure and management of affected patients so that there is a wide variation of the outcome, in particular of pre-symptomatically diagnosed patients. At this time of rapid expansion of neonatal screening for GCDH deficiency, the major aim of this guideline is to re-assess the common practice and to formulate recommendations for diagnosis and management of GCDH deficiency based on the best available evidence.

AB - Glutaryl-CoA dehydrogenase (GCDH) deficiency is an autosomal recessive disease with an estimated overall prevalence of 1 in 100 000 newborns. Biochemically, the disease is characterized by accumulation of glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine, which can be detected by gas chromatography-mass spectrometry of organic acids or tandem mass spectrometry of acylcarnitines. Clinically, the disease course is usually determined by acute encephalopathic crises precipitated by infectious diseases, immunizations, and surgery during infancy or childhood. The characteristic neurological sequel is acute striatal injury and, subsequently, dystonia. During the last three decades attempts have been made to establish and optimize therapy for GCDH deficiency. Maintenance treatment consisting of a diet combined with oral supplementation of L-carnitine, and an intensified emergency treatment during acute episodes of intercurrent illness have been applied to the majority of patients. This treatment strategy has significantly reduced the frequency of acute encephalopathic crises in early-diagnosed patients. Therefore, GCDH deficiency is now considered to be a treatable condition. However, significant differences exist in the diagnostic procedure and management of affected patients so that there is a wide variation of the outcome, in particular of pre-symptomatically diagnosed patients. At this time of rapid expansion of neonatal screening for GCDH deficiency, the major aim of this guideline is to re-assess the common practice and to formulate recommendations for diagnosis and management of GCDH deficiency based on the best available evidence.

UR - http://www.scopus.com/inward/record.url?scp=33846452131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846452131&partnerID=8YFLogxK

U2 - 10.1007/s10545-006-0451-4

DO - 10.1007/s10545-006-0451-4

M3 - Article

C2 - 17203377

AN - SCOPUS:33846452131

VL - 30

SP - 5

EP - 22

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 1

ER -